Literature DB >> 24344259

Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines.

Yuan Lu1, John P Welsh, James R Swartz.   

Abstract

The rapid dissemination of the 2009 pandemic H1N1 influenza virus emphasizes the need for universal influenza vaccines that would broadly protect against multiple mutated strains. Recent efforts have focused on the highly conserved hemagglutinin (HA) stem domain, which must undergo a significant conformational change for effective viral infection. Although the production of isolated domains of multimeric ectodomain proteins has proven difficult, we report a method to rapidly produce the properly folded HA stem domain protein from influenza virus A/California/05/2009 (H1N1) by using Escherichia coli-based cell-free protein synthesis and a simple refolding protocol. The T4 bacteriophage fibritin foldon placed at the C terminus of the HA stem domain induces trimer formation. Placing emphasis on newly exposed protein surfaces, several hydrophobic residues were mutated, two polypeptide segments were deleted, and the number of disulfide bonds in each monomer was reduced from four to two. High pH and Brij 35 detergent emerged as the most beneficial factors for improving the refolding yield. To stabilize the trimer of the HA stem-foldon fusion, new intermolecular disulfide bonds were finally introduced between foldon monomers and between stem domain monomers. The correct immunogenic conformation of the stabilized HA stem domain trimer was confirmed by using antibodies CR6261, C179, and FI6 that block influenza infection by binding to the HA stem domain trimer. These results suggest great promise for a broadly protective vaccine and also demonstrate a unique approach for producing individual domains of complex multimeric proteins.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24344259      PMCID: PMC3890838          DOI: 10.1073/pnas.1308701110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

Review 1.  Protein identification and analysis tools in the ExPASy server.

Authors:  M R Wilkins; E Gasteiger; A Bairoch; J C Sanchez; K L Williams; R D Appel; D F Hochstrasser
Journal:  Methods Mol Biol       Date:  1999

Review 2.  Recombinant trivalent influenza vaccine (flublok(®)): a review of its use in the prevention of seasonal influenza in adults.

Authors:  Lily P H Yang
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

3.  Vaccine preparedness--are we ready for the next influenza pandemic?

Authors:  Peter F Wright
Journal:  N Engl J Med       Date:  2008-06-12       Impact factor: 91.245

Review 4.  Advances in refolding of proteins produced in E. coli.

Authors:  H Lilie; E Schwarz; R Rudolph
Journal:  Curr Opin Biotechnol       Date:  1998-10       Impact factor: 9.740

5.  Cell-based flu vaccines ready for US prime time.

Authors:  Andy Extance
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

6.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Authors:  Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

7.  Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus.

Authors:  James Stevens; Adam L Corper; Christopher F Basler; Jeffery K Taubenberger; Peter Palese; Ian A Wilson
Journal:  Science       Date:  2004-02-05       Impact factor: 47.728

8.  Attacking the flu: neutralizing antibodies may lead to 'universal' vaccine.

Authors:  Grace L Chen; Kanta Subbarao
Journal:  Nat Med       Date:  2009-11       Impact factor: 53.440

9.  Development of cell-free protein synthesis platforms for disulfide bonded proteins.

Authors:  Aaron R Goerke; James R Swartz
Journal:  Biotechnol Bioeng       Date:  2008-02-01       Impact factor: 4.530

10.  Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies.

Authors:  Audray K Harris; Joel R Meyerson; Yumiko Matsuoka; Oleg Kuybeda; Amy Moran; Donald Bliss; Suman R Das; Jonathan W Yewdell; Guillermo Sapiro; Kanta Subbarao; Sriram Subramaniam
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-04       Impact factor: 11.205

View more
  78 in total

1.  Assessing sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery.

Authors:  Yuan Lu; Wei Chan; Benjamin Y Ko; Christopher C VanLang; James R Swartz
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-21       Impact factor: 11.205

Review 2.  Progress on adenovirus-vectored universal influenza vaccines.

Authors:  Kui Xiang; Guan Ying; Zhou Yan; Yan Shanshan; Zhang Lei; Li Hongjun; Sun Maosheng
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Proteomic contributions to our understanding of vaccine and immune responses.

Authors:  Allison C Galassie; Andrew J Link
Journal:  Proteomics Clin Appl       Date:  2015-09-10       Impact factor: 3.494

Review 4.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

Review 5.  The growing impact of lyophilized cell-free protein expression systems.

Authors:  J Porter Hunt; Seung Ook Yang; Kristen M Wilding; Bradley C Bundy
Journal:  Bioengineered       Date:  2016-10-28       Impact factor: 3.269

Review 6.  Cell-Free Synthetic Biology: Engineering Beyond the Cell.

Authors:  Jessica G Perez; Jessica C Stark; Michael C Jewett
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-12-01       Impact factor: 10.005

Review 7.  Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Hemagglutinin Stem.

Authors:  Sarah F Andrews; Barney S Graham; John R Mascola; Adrian B McDermott
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

Review 8.  Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential for a Universal Influenza Vaccine.

Authors:  James E Crowe
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

9.  Order and disorder control the functional rearrangement of influenza hemagglutinin.

Authors:  Xingcheng Lin; Nathanial R Eddy; Jeffrey K Noel; Paul C Whitford; Qinghua Wang; Jianpeng Ma; José N Onuchic
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-31       Impact factor: 11.205

10.  Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus.

Authors:  Maya Sangesland; Larance Ronsard; Samuel W Kazer; Julia Bals; Seyhan Boyoglu-Barnum; Ashraf S Yousif; Ralston Barnes; Jared Feldman; Maricel Quirindongo-Crespo; Patrick M McTamney; Daniel Rohrer; Nils Lonberg; Bryce Chackerian; Barney S Graham; Masaru Kanekiyo; Alex K Shalek; Daniel Lingwood
Journal:  Immunity       Date:  2019-09-25       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.